drug
TOLVAPTAN
Marketedupdated 5mo agoby Otsuka America Pharmaceutical Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying TOLVAPTAN
- phase3A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- phase3A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- —Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
- phase1A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
- phase1Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male
- phase1Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol
- —Samsca PMS in ADPKD Patients
- phase2A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 7, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Apr 7, 2030formulationUS 109056943.5y
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
- Sep 1, 2026compositionUS 8501730
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that